← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksCORTPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Corcept Therapeutics Incorporated (CORT) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026

Current Price
$35.70
Market reference
Price Target
$68.40
+91.6% Upside
Target Range
$30.00 — $100.00
Very wide disagreement
Analyst Rating
Buy
24 analysts
Forward P/E97.6x
Trailing P/E43.5x
Forward PEG—
Implied Growth-55.8%
Median Target$67.00
Analyst Spread102.3%

Analysts see +91.6% upside to their consensus target of $68.40. The bullish rating consensus aligns with positive price target gap.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$35.70
Consensus$68.40
High$100.00
Low$30.00
Model$52.59
Bear Case
$30
-16.0%
Consensus
$68
+91.6%
Bull Case
$100
+180.1%
Valuation Model TargetsConfidence: 50/100
Bear$19
Base$53
Bull$214

Analyst Ratings Distribution

Breakdown of 24 published analyst recommendations for CORT

38% hold / mixed conviction
+23
BearishBullish
Weighted analyst sentiment score based on 24 ratings
ConsensusBuy
Coverage24 Analysts
Net Score+23
Bull / Bear54% / 8%
Strong Buy00%
Buy1354%
Hold938%
Sell28%
Strong Sell00%
Strong Buy
00%
Buy
1354%
Hold
938%
Sell
28%
Strong Sell
00%
Recommendation Mix54% Buy · 38% Hold · 8% Sell
Buy (13)Hold (9)Sell (2)

CORT Price Target Analysis

Updated March 1, 2026

As of March 1, 2026, Corcept Therapeutics Incorporated (CORT) has a Wall Street consensus price target of $68.40, based on estimates from 24 covering analysts. With the stock currently trading at $35.70, this represents a potential upside of +91.6%. The company has a market capitalization of $3.78B.

Analyst price targets range from a low of $30.00 to a high of $100.00, representing a 102% spread in expectations. The median target of $67.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.

The current analyst consensus rating is Buy, with 13 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.

From a valuation perspective, CORT trades at a trailing P/E of 43.5x and forward P/E of 97.6x. Analysts expect EPS to grow -55.8% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $52.59, with bear and bull scenarios of $18.99 and $214.48 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+35.3%
Avg Forward P/E34.4x
Peers with Coverage10 / 10
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
AGIOAgios Pharmaceuticals, Inc.$2.3T$30.23$41.50+37.3%Buy—29
VRTXVertex Pharmaceuticals Incorporated$126.2B$496.83$545.08+9.7%Buy25.7x55
ASNDAscendis Pharma A/S$14.3B$233.50$286.50+22.7%Buy49.1x24
BBIOBridgeBio Pharma, Inc.$12.9B$66.48$98.92+48.8%Buy—26
BMRNBioMarin Pharmaceutical Inc.$11.9B$61.73$82.00+32.8%Buy15.4x40
COGTCogent Biosciences, Inc.$6.3B$38.85$48.13+23.9%Buy—12
PTCTPTC Therapeutics, Inc.$5.5B$68.19$84.50+23.9%Buy—26
MIRMMirum Pharmaceuticals, Inc.$4.8B$92.29$114.20+23.7%Buy—18
FOLDAmicus Therapeutics, Inc.$4.4B$14.37$14.33-0.3%Buy47.4x24
CRNXCrinetics Pharmaceuticals, Inc.$3.9B$41.10$94.71+130.4%Buy—18

Upside Potential Comparison

CRNX
+130.4%
BBIO
+48.8%
AGIO
+37.3%
BMRN
+32.8%
PTCT
+23.9%
COGT
+23.9%
MIRM
+23.7%
ASND
+22.7%

See CORT's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is CORT Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare CORT vs AGIO

See how CORT stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

What is the CORT stock price target for 2026?

The consensus Wall Street price target for CORT is $68.4, representing 91.6% upside from the current price of $35.7. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is CORT a buy, sell, or hold?

CORT has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 13 Buy/Strong Buy ratings. The consensus 12-month price target of $68.4 implies 91.6% upside from current levels.

Is CORT stock overvalued or undervalued?

At a forward P/E of 97.6477x, CORT trades at a premium valuation. The consensus price target of $68.4 (91.6% upside) suggests analysts still see growth justifying the multiple.

How high can CORT stock go?

The most bullish Wall Street analyst has a price target of $100 for CORT, while the most conservative target is $30. The consensus of $68.4 represents the median expectation. Our quantitative valuation model projects a bull case target of $214 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover CORT stock?

CORT is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 9 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the CORT stock forecast?

The 12-month CORT stock forecast based on 24 Wall Street analysts shows a consensus price target of $68.4, with estimates ranging from $30 (bear case) to $100 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $53, with bear/bull scenarios of $19/$214.

What is CORT's fair value based on fundamentals?

Our quantitative valuation model calculates CORT's fair value at $53 (base case), with a bear case of $19 and bull case of $214. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.

What is CORT's forward P/E ratio?

CORT trades at a forward P/E ratio of 97.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 43.5x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy CORT stock?

Wall Street analysts are very optimistic on CORT, with a "Buy" consensus rating and $68.4 price target (91.6% upside). 13 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do CORT price targets vary so much?

CORT analyst price targets range from $30 to $100, a 102% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $68.4 consensus represents the middle ground. Our model's $19-$214 range provides an independent fundamental perspective.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.